A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe

Table 8 The expected annual healthcare budget impact of adopting BUCCOLAM

	Scotland	Wales	Germany	Spain	France	Italy	Switzerland
Population aged 0–18 years		2,993,000	12,662,656		15,226,230	10,831,152	1,469,605
Prevalence rate			0.45%		0.50%	0.75%	0.45%
Absolute prevalence			57,558	100,000	76,131	81,234	6,680
Proportion receiving rescue medication			48.0%		30.0%		96.7%
Absolute number receiving rescue medication		2,737	27,628		22,839		6,457
Expected one-year mortality ^a		0.02%
Patients alive to receive treatment ^a		2,736
Proportion eligible to receive BUCCOLAM			70%	25%	110% ^b		80%
Number of patients eligible	6,820		19,339	25,000	25,123		5,166
Market share in first year	50.0%	50.0%	10.0%	48%	17.9%	10.0%	36.7%
Number of patients transferring from current care to BUCCOLAM	3,410	1,368	1,934	12,000	4,504	8,123	1,894
Incremental saving per patient ^c	€399	€607	€3,507	€5,484	€2,637	€1,540	€9,397
Total expected saving ^d	€1,361,549	€830,203	€6,783,169	€65,811,104	€11,877,804	€12,507,399	€17,801,274

^a Information on mortality is required in the Welsh health technology assessment submission template, and this was provided in addition to the base case calculation of the budget impact of BUCCOLAM. For other countries, this was not included, as mortality rates are low and not expected to be substantially impacted by the rescue medication given.
^b In France, it was expected that the number of children being prescribed rescue medication would increase over current levels with the availability of BUCCOLAM.
^c The incremental saving per patient is taken from Table 7 (Breakdown of base case incremental costs of BUCCOLAM versus standard care, one-year time horizon).
^d The total expected saving is calculated as the product of the incremental saving per patient and the number of patients transferring from current care to BUCCOLAM.

ISSN: 2191-1991